Get started

Medical

Vijaya Diagnostics: Rukega Nahi SaalaPrice is at ATH. You can tell this in strong bullish trend even at first glance. Trend is very strong even if you buy at current ATH 1250 and hold, it can be decent swing trade. Of course price will make a higher swing low. Maybe best range will be around 1070-1085. Trend direction - Bullish Confirmed. Trade direction - Bullish confirmed aligned with long term trend. Entry : 1070-1085. SL : 1035 (book half here) Final SL: 1000 (Exit completely) Target: Current ATH 1250. Risk Reward: 1:5 If you can just wait for optimal entry, you reduce your SL risk significantly. These are types of trades where chart actually invites you to enter, should be never avoided. At least enter with 10qty. You never know compounding effect. This is what I call high quality trade. - Clear Trend established with no confusion, even in bearish market - No sign of exhaustion
NSE:VIJAYALong
by vkfinserv
Healthcare Sector Poised For A 7% to 15% Rally Into Early 2025My continued research to help traders shows the US Healthcare and Biotech sectors are poised for a very large rally phase into early 2025. Particularly, XLV and XBI seem uniquely setup to rally more than 9-10% over the next 60 to 90+ days. This video explains how I use my Adaptive Dynamic Learning Predictive Modeling system to find opportunities other people miss. Using technology, predictive modeling, and inference engines like this is one advantage I have because I can build any type of technology or system I like - and use it on any symbol or interval I like. Now is the time to prepare for the big moves headed into 2025. Follow my research if you want to target the biggest price swings in the markets. Get some. #trading #research #investing #tradingalgos #tradingsignals #cycles #fibonacci #elliotwave #modelingsystems #stocks #bitcoin #btcusd #cryptos #spy #es #nq #gold
AMEX:XLVLong
by BradMatheny
NASDAQ: SBC, Empowering the Growth of Aesthetic MedicalSBC Medical Group Holdings (NASDAQ: SBC) is making waves in the aesthetic medicine industry with its dynamic growth strategy and robust franchise model. Analysts at Zacks have set a target price of $15.40, reflecting confidence in SBC's ability to scale its operations and expand internationally. With a current share price of $6.80 (as of November 2024), the company presents a compelling case for investors seeking growth in an underpenetrated market. Dominance in Japan’s Growing Market SBC operates the largest network of franchised clinics in Japan, with 220 locations under various brands, capturing an estimated 31% market share. Despite its leadership, the Japanese aesthetic medicine market remains relatively untapped, with just 10% penetration. The company treated 3.9 million patients in 2023, a 26% increase from 2021, highlighting the growing demand driven by social media and demographic trends. Comprehensive Solutions and Strong Financials SBC's franchisees benefit from a comprehensive suite of services, including administrative support, marketing, procurement, and technology integration. These offerings enable clinics to focus on high-quality, affordable patient care while expanding their service portfolios. The company’s financial performance reflects its growth momentum, with revenue reaching $193 million in 2023, up 10% year-over-year. A 5-year revenue CAGR of 24% underscores the scalability of its model, supported by a strong EBITDA margin of 42.5% and a robust cash position of $103.7 million. Global Expansion Strategy SBC’s international operations in Vietnam and California signal the early stages of a broader global strategy. The clinics cater to rising demand for popular treatments like liposuction and eyelid surgery, aligning with global trends in non-invasive and surgical procedures. With the global aesthetic medicine market projected to grow from $59.8 billion in 2024 to $81.7 billion by 2032, SBC is well-positioned to capture a significant share. Outlook and Investor Potential The $15.40 target price reflects optimism about SBC’s continued network expansion and revenue growth. While challenges like foreign exchange risks and competitive pressures persist, the company’s innovative approach and financial discipline mitigate these risks. SBC Medical Group stands out as a growth-oriented player in a burgeoning industry. With its proven franchise model and strategic vision, the company offers investors an attractive opportunity to tap into the expanding global aesthetic medicine market.
NASDAQ:SBCLong
by HASHInvests200
MPW at these levels look to be a 20%+ gain within 6-12 monthsI have traded this stock for awhile now and going in and out of it can make you some decent gains. You can see on this chart the upside and downside of it. It has been hit recently because of the default by one of their big tenants. However, this is a fundamentally strong business that will come through that and start to see better results, especially in an interest rate declining environment. I look at this as a minimum 20% upside play in the next 3-6months based on previous timelines, and you could see this run depending on how they navigate coming around the loss of that client. I started a position in the sub $4 range and will look to add to it on any dips due to market dynamics.
NYSE:MPWLong
by jasonbc
Baxter International | BAX | Long at $35.00Baxter International NYSE:BAX , a company that primarily focuses on products to treat kidney disease and other chronic and acute medical conditions, is another name that had a very rough time through 2022 and into 2024. However, the company's projected earnings and cash flow are expected to grow from 2024 through 2027 and it currently has a 3.35% dividend. Interest rates being lowered soon will help these projections. From a technical analysis perspective, my selected simple moving average is working its way down to recapture the price for a likely reversal in the next year or two (unless company fundamentals change). The recent low in June 2024 was higher than the previous low in October 2023 (higher lows) indicating a high chance of future price improvement - but nothing is guaranteed. At $35.00, it is currently in a personal buy zone. Target #1 - $40.00 Target #2 - $48.00 Target #3 - $51.50 Target #4 - $65.00 Target #5 - $77.00 (very long-term...)
NYSE:BAXLong
by WorthlessViews
A promising drug for immunotherapy of solid tumorsKey arguments in support of the idea ▪ Initial clinical data for CLN-619 are pending. Investment thesis Cullinan Therapeutics is a clinical-stage biopharmaceutical company developing drugs for the treatment of cancer. On 1 June, Cullinan Therapeutics will present data from a Phase I clinical trial of its CLN-619 drug. The results of early-phase studies will determine the potential of the experimental drug CLN-619 for immunotherapy of solid tumors and hematological malignancies. At the upcoming 2024 ASCO Annual Meeting, the Company will present new data from the Phase 1 study (NCT05117476) of CLN619 in patients with solid tumors. The monoclonal antibody CLN619 binds to receptors on the tumor surface and increases theproduction of proteins recognized by immune system cells that attack the tumor. Cullinan Therapeutics is exploring the therapeutic potential of CLN-619 as a monotherapy for cancers and in combination with KEYTRUDA (pembrolizumab). The study results announced last week indicated a favorable safety profile for the drug and we expect the presentation to confirm its therapeutic potential and the ability to progress into further phases of the study. In addition, a second Phase 1 study in patients with multiple myeloma will be initiated in the coming months. Cullinan Therapeutics has a diversified pipeline of immunotherapy drugs with various mechanisms, including a latestage anti-tumor drug. One of the lead candidates, developed jointly with Taiho Oncology, is zipalertinib for the treatment of NSCLC. The Company continues to actively enroll patients in its Phase 3 study designed to evaluate the efficacy of zipalertinib as a first-line therapy for NSCLC. In addition, in the second half of the year, Cullinan Therapeutics will present the first results from the Phase 1 clinical trials on its CLN-049 and CLN-418 candidates for the immunotherapy of recurrent hematologic oncohematologic diseases and various types of solid tumors, respectively. We set a Buy rating on CGEM stock with a 2-month price target of $29.5. A stop loss order is recommended at $20.5.
NASDAQ:CGEMLong
by FreedomHolding
PILL 3x Leverage Medical/ Pharma ETF for swing LONGAMEX:PILL On the 4H Chart, current market price is sitting on the support of order blocks and the EMA200, while in an uptend from a double bottom in the sprint. It is moving into the high volume area of the voluxme profile. For the swing trade, the stop loss is $0.10 below the EMA200 while the targets are marked based on a combination of the horizontal resistances of prior swing pivots along with sell order blocks and the structure of the volume profile. Accordingly, this trade risks $0.60 for about $ 4 to $ 5 of upside making for an excellent swing setup especially since healthcare, medical and pharmacueticals are known to be recession resilient and ETFs are inherently diversified making leveraging a risk probably worth taking.
AMEX:PILLLong
by AwesomeAvani
LABU / LABD Medical Leveraged ETFs Flip Strategy.LABU is shown here on a 2H time frame. I am holding 500 shares having bought November 14th on golden cross of fast and slow hull moving averages. The unrealized gain is 50%. Here, I determine that I should en bloc or in increments close the position. First, on the dual time RSI indicator of Chris Moody, the RSI is now over 60 and approaching 65. Price pivoted when RSI was in this range as shown by the red down arrows on the chart. A fibonacci analysis is that the LABU downtrend of early September to late October has now retraced in the range of 50% with the mid levels shown on the chart from the drawing tool. Because of these two considerations, I believe that I should bank the 50% profit in less than 3 weeks and perhaps take a position in the inverse ETF LABD. I will do this on a 15 minute time frame, take off one fifth of the position daily at the high of day as determined by an alert for the faster Hull Moving Average doing down instead of upsloping. At the same time on the LABD 15 minute chart I will buy a corresponding position at the low of day again using an alert. By the end of the five days, the LABU position will be closed and the profits redeployed into LABD. When LABD retraces 505 of its downtrend and RSI rises above 60, I will consider fading the position and retaking a position in LABU. thus toggling positions in the inverse ETFs as analysis and indicators dictate.
AMEX:LABULong
by AwesomeAvani
1
Baxter Inc. (BAX) bullish scenario:The technical figure Falling Wedge can be found in the daily chart in the US company Baxter International Inc. (BAX). Baxter International Inc. is an American multinational healthcare company. The company primarily focuses on products to treat kidney disease, and other chronic and acute medical conditions. The Falling Wedge broke through the resistance line on 22/03/2023. If the price holds above this level, you can have a possible bullish price movement with a forecast for the next 9 days towards 41.98 USD. According to experts, your stop-loss order should be placed at 37.35 USD if you decide to enter this position. U.S. scientific instruments maker Thermo Fisher Scientific Inc and South Korea's Celltrion Inc are among those competing to acquire the biopharma solutions business of medical device maker Baxter International Inc, according to people familiar with the matter. The divestment, which the sources said could fetch more than $4 billion, would help Baxter pay down debt following its $10.5 billion acquisition of medical device maker Hill-Rom Holdings in 2021. Baxter, which has a market value of $19 billion, had total debt of $16.6 billion as of the end of December. Private equity firms, including KKR & Co and Carlyle Group, have also expressed interest in the Baxter business, the sources said. Other bidders could still emerge, they added. Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals and cannot be held liable nor guarantee any profits or losses.
NYSE:BAXLong
by legacyFXofficial
Fresenius (FRE.de) bearish scenario:The technical figure Channel Up can be found in the daily chart in the German company Fresenius SE & Co. KGaA (FRE.de). Fresenius SE & Co. KGaA is a European multinational healthcare company. It provides products and services for dialysis in hospitals and inpatient and outpatient medical care. It is involved in hospital management and in engineering and services for medical centers and other healthcare facilities. Channel Up broke through the support line on 24/02/2023. If the price holds below this level, you can have a possible bearish price movement with a forecast for the next 15 days towards 24.00 EUR. According to experts, your stop-loss order should be placed at 29.710 EUR if you decide to enter this position. Fresenius SE is exploring steps to relinquish control of its dialysis subsidiary as Elliott Investment Management puts pressure on the German healthcare company to simplify its business. Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses.
XETR:FREShort
by legacyFXofficial
GMVD | A Low Float Monster | Oversold G Medical Innovations Holdings Ltd, together with its subsidiaries, an early commercial stage healthcare company, engages in the development of next generation mobile health and telemedicine solutions in the United States, China, and Israel. The company's products include Prizma, a plug-and-play medical device that measures vital signs with electronic medical records functionality and clinical grade reporting standards; and Extended Holter Patch System, a multi-channel patient-worn biosensor that captures electrocardiogram data continuously for up to 14 days. It also develops Wireless Vital Signs Monitoring System, a solution that provides continuous real time monitoring of vital signs and biometrics. In addition, it offers monitoring services, including independent diagnostic testing facility monitoring and private monitoring services. The company was incorporated in 2014 and is based in Rehovot, Israel.
GLong
by DivergenceSeeker
2
ATIP | I Spy An Insider Buy | LONGATI Physical Therapy, Inc. operates as an outpatient physical therapy provider that specializes in outpatient rehabilitation and adjacent healthcare services in the United States. It offers a range of services to its patients, including physical therapy to treat spine, shoulder, knee, and neck injuries or pain; work conditioning and work hardening; and hand therapy, aquatic therapy, functional capacity assessment, and wellness programs. It also provides ATI worksite solutions comprising injury prevention programs, work-related injury assessment services, wellness offerings, and consultations for employers; proprietary electronic medical records (EMR) integration, caseload management, and continuing education in progressive therapies; and sports medicine, including onsite sports physical therapy, clinical evaluation and diagnosis, immediate and emergency care, nutrition programs, and concussion management services. The company offers outpatient physical therapy services under the ATI Physical Therapy name. As of December 31, 2021, it had 910 owned and 20 managed clinics. ATI Physical Therapy, Inc. was founded in 1996 and is based in Bolingbrook, Illinois.
ALong
by DivergenceSeeker
LABU target price based on pitchfork analysisTwo pitchfork lines (one with dashed lines and one with sold lines) neatly matched their bottom lines. The price (approximately) reached that level 5 times. Further, the solid's middle red line matches pretty well the dashed pitchfork top lines. All these makes for a more confident prediction(s). The first is that the price will reach above 14 (the top dashed line), as marked. That would be above 75% increase from current price. At that point the price may or may not temporarily fall back after which I expect to continue up reaching above 22 (the marked top solid pitchfork line). That's over 175% profit. I have been long on LABU since 6.47 (as posted elsewhere).
AMEX:LABULong
by TradersForecast
4DXNEWS CAT 1JUL "4DMedical signs deal to supply lung imaging technology to Australian radiology clinics" Looking for Option A Or Looking for Option B Option B would provide a nice entry if we could flush down into that lower TF range in Blue. This range was the last range on the 5 minute chart that sent the price moving a lot higher. 22% approx. Trigger is a break of the falling resistance line. Confluence is a move above the 10day EMA, Above VWAP, a reclaim of the RL range marked on the chart.
ASX:4DXLong
by gillman_hugh
$TLRY blue dream sniper 👁‍🗨*This is not financial advice, so trade at your own risks* *My team digs deep and finds stocks that are expected to perform well based off multiple confluences* *Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management* Today team purchased shares of marijuana company Tilray Brands $TLRY at $6.10 per share. Our take profit is $7 with a stop loss at $5.90. Our Entry: $6.10 Take Profit: $7 Stop Loss: $5.90 If you want to see more, please like and follow us @SimplyShowMeTheMoney
NASDAQ:TLRYLong
by SimplyShowMeTheMoney
3
$GE earnings analysis *This is not financial advice, so trade at your own risks* *My team digs deep and finds stocks that are expected to perform well based off multiple confluences* *Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management* My team has been digging into global tech company $GE for the past few days in anticipation of their upcoming earnings report. $GE continues to be a dominate power in air travel (aerospace engines), precision public health (medical diagnostic equipment), and energy transition (steam and wind turbines). This company is a triple threat and certainly not a force to be reckoned with. $GE has a great technical set-up right now on the charts as well. If $GE has an earnings beat pre-market expect current resistance at $115-116 to be broken sometime during the day. My team still has yet determined a good take profit on $GE due to a lack of uncertainty in the companies potential. However we believe that $145 is a key zone to look at if an uptrend does emerge. My team entered $GE on 10/25/21 at $104 per share. This is a long term trade. Earnings are expected to be announced premarket on 10/26/21. If you want to see more, please like and follow us @SimplyShowMeTheMoney
NYSE:GELong
by SimplyShowMeTheMoney
2